Related Experiment Video
Updated: Jun 10, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Pazopanib: in advanced renal cell carcinoma
Mark Sanford1, Gillian M Keating
1Adis, 41 Centorian Drive, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz
Summary
Pazopanib significantly improved progression-free survival (PFS) in advanced renal cell carcinoma patients. This oral tyrosine kinase inhibitor demonstrated better outcomes across various patient subgroups compared to placebo.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Renal cell carcinoma (RCC) is a significant cause of cancer-related mortality.
- Targeted therapies are crucial for managing advanced and metastatic RCC.
- Pazopanib is an oral multi-tyrosine kinase inhibitor investigated for its anti-cancer properties.
Purpose of the Study:
- To evaluate the efficacy and safety of pazopanib in patients with advanced or metastatic renal cell carcinoma.
- To compare progression-free survival (PFS) and overall response rate (ORR) between pazopanib and placebo treatments.
Main Methods:
- A randomized, double-blind, placebo-controlled, multinational clinical trial.
- Patients with locally advanced or metastatic renal cell carcinoma received pazopanib 800 mg once daily or placebo.
- Progression-free survival (PFS), overall response rate (ORR), and adverse events were assessed.
Main Results:
- Pazopanib significantly increased median PFS compared to placebo (9.2 vs 4.2 months; hazard ratio 0.46).
- Pazopanib demonstrated superior PFS across all prespecified patient subgroups.
- A significantly higher ORR was observed in pazopanib recipients, with a median response time of 11.9 weeks and duration of 58.7 weeks.
Conclusions:
- Pazopanib is an effective treatment for advanced or metastatic renal cell carcinoma, significantly improving PFS and ORR.
- Pazopanib exhibits an acceptable tolerability profile, with adverse events generally being mild to moderate.
- The benefits of pazopanib were consistent across diverse patient populations.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...